Medical Specialty >> Pharmacy
Some Steroid Meds May Raise Coronavirus Risk
12:00 PM CDT.
Read article
- How One Patient’s Battle With COVID-19 Changed U.S. Testing Protocols
- A Pill Left Out, a Child’s Life Lost: Maisie’s Story a Warning to All Adults
- Amid COVID-19 Crisis, Blood Donor Restrictions Eased for Gays
- Newbies More Apt to Have Bad Reaction to Marijuana: Study
JOURNAL UPDATE
Initial Invasive Strategy No Better in Stable Coronary Disease
7:00 PM CDT. But invasive strategy may improve angina-related status in those with coronary disease, ischemia- Hydroxychloroquine Can Shorten Time to Recovery in COVID-19
- Bacteremia Risk Higher in Older Patients Hospitalized With IBD
- Model Shows Hep C-Infected Kidney Transplants Beneficial, Cost-Effective
MONTHLY JOURNAL SUMMARY
March 2020 Briefing - Pharmacy
April 01, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Bevacizumab for breast cancer: FDA grants a stay of execution
Dr. Alberto De la Guerra.
The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.
MEDICAL FOCUS
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
